Evidence map›Paper›PMID 39844400›Full record

ReviewCurrent drug targets2025

MT1JP: A Pivotal Tumor-Suppressing LncRNA and its Role in Cancer Progression and Therapeutic Potential.

Haodong He, Jingjie Yang, Wenjin Peng, Moyu Li, Meiyan Shuai, Faming Tan, Zheng Cao, Chengfu Yuan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Haodong HeHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, 443002, China.ORCID 0009-0002-5779-1395
Jingjie YangHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, 443002, China.
Wenjin PengHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, 443002, China.
Moyu LiHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, 443002, China.
Meiyan ShuaiHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, 443002, China.
Faming TanCollege of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, China.
Zheng CaoCollege of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, China.
Chengfu YuanHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, 443002, China.ORCID 0000-0002-1894-0960

Funding

innovational group project of Hubei Province Natural Science Foundation in China 2021CFA015Joint Fund Project of Hubei Province Natural Science Foundation in China 2024AFD231National Natural Science Foundation of China 82174035, 82374107Open Foundation for Tumor Microenvironment and Immunotherapy Key Laboratory of Hubei Province in China 2023KZL01Traditional Chinese Medicine Science and Technology Research and Development Special Project of Yichang Public Hospital Reform and High-quality Development Demonstration Project in China YWGZ24-06, YWGZ24-05
6 · The paper itself

Abstract

Metallothionein 1J pseudogene (MT1JP) is a long non-coding RNA (lncRNA) that functions as a tumor suppressor in various malignancies. Reduced MT1JP expression is associated with increased tumor proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), and treatment resistance in nine cancers, such as gastric cancer, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and breast cancer. Mechanistically, MT1JP acts as a competitive endogenous RNA (ceRNA) to regulate oncogenic microRNAs (miRNAs), including miR-92a-3p, miR-214-3p, and miR-24-3p. This regulation restores tumor suppressor genes, such as FBXW7, RUNX3, and PTEN, thereby disrupting oncogenic pathways, including PI3K/AKT, Wnt/β- catenin, and p53, promoting apoptosis, and inhibiting tumor progression. Clinically, MT1JP expression correlates with tumor grade, differentiation, TNM stage, lymph node metastasis, and patient prognosis, suggesting its potential as a diagnostic and prognostic biomarker. Furthermore, its therapeutic potential in RNA-based treatments has attracted significant attention. Despite these findings, questions remain regarding its role in epigenetic regulation, transcriptional control, and RNA delivery. This review explores the molecular mechanisms underlying MT1JP, highlighting its clinical relevance and potential as a therapeutic target. Future research should focus on elucidating its role in epigenetic regulation, overcoming challenges in therapeutic delivery, and validating its utility as a biomarker for different cancers. MT1JP holds promise for advancing precision oncology by providing innovative approaches for cancer diagnosis and treatment.

Indexed as

MetallothioneinNeoplasmsRNA, Long NoncodingAnimalsBiomarkers, TumorDisease ProgressionEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansMicroRNAsBiomarkers, TumorMetallothioneinMicroRNAsRNA, Long NoncodingCancerLncRNAMT1JPprognosispseudogenes.targeted therapy

Identifiers

PMID39844400

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.